Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study

Table 4 Effect of tapering DQ on maintaining ASDAS-ID in patients who achieved ASDAS-ID at 1-year follow-up

	Number (%) of 1-year intervals maintained the ASDAS-ID	Univariable modelOR (95% CI) (n = 230–236)	Baseline model* OR (95% CI) (n = 236)	Longitudinal model^† OR (95% CI) (n = 236)
Group according to the interval DQ
Control group (DQ = 100)	122 (65.6)	Reference	Reference	Reference
Mild-tapering group (50 ≤ DQ < 100)	84 (69.4)	1.16 (0.70–1.45)	1.22 (0.73–2.04)	1.25 (0.41–3.80)
Heavy-tapering group (DQ < 50)	10 (50.0)	0.58 (0.23–1.45)	0.57 (0.23–1.41)	0.19 (0.05–0.74)
QIC of the model		422.244	413.739	407.520

ASDAS Ankylosing Spondylitis Disease Activity Score, CI confidence interval, DQ dose quotient, OR odds ratio, QIC quasi-likelihood under the independence model criterion
*The model was adjusted for age, sex, and baseline ASDAS-CRP
^†The model was adjusted for covariates in the baseline model, ASDAS_t − 1, concomitant NSAID, and interaction between ASDAS_t − 1 and group

ISSN: 1478-6362